Evidence map›Paper›PMID 33687516›Full record

ArticleEuropean journal of clinical pharmacology2021

SGLT2 inhibitors and euglycemic diabetic ketoacidosis.

Zohaib Yousaf, Fateen Ata, Adeel Ahmad Khan, Almurtada Razok, Jaweria Akram, Elrazi Awadelkarim Hamid Ali, Ahmed Abdalhadi, Mohammed I Danjuma, Dabia Hamad S H Al Mohanadi

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Zohaib YousafDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Fateen AtaDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar. docfateenata@gmail.com.ORCID 0000-0001-7121-8574
Adeel Ahmad KhanDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Almurtada RazokDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Jaweria AkramDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Elrazi Awadelkarim Hamid AliDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Ahmed AbdalhadiDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Mohammed I DanjumaDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.
Dabia Hamad S H Al MohanadiDepartment of Medicine, Hamad Medical Corporation, PO Box 3050, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Diabetic KetoacidosisSodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID33687516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.